Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Thackray Helen M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-7,525Price:$5.08
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Milano VincentOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:999Price:$5.63
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Heggie TheresaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:999Price:$5.63
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Stonehouse Jon POwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:10,000Price:--
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Stonehouse Jon POwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:10,000Price:--
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Stonehouse Jon POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-20,000Price:--
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Thackray Helen M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-5,580Price:$6.05
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Stonehouse Jon POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-14,089Price:$6.05
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Gayer Charles KOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,482Price:$6.05
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Doyle AnthonyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,482Price:$6.05
Filings by filing date
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Thackray Helen M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-7,525Price:$5.08
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Milano VincentOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:999Price:$5.63
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Heggie TheresaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:999Price:$5.63
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Stonehouse Jon POwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:10,000Price:--
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Stonehouse Jon POwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:10,000Price:--
-
Jan 03, 2024 (filed on Jan 04, 2024)Insider Name:Stonehouse Jon POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-20,000Price:--
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Thackray Helen M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-5,580Price:$6.05
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Stonehouse Jon POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-14,089Price:$6.05
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Gayer Charles KOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,482Price:$6.05
-
Dec 19, 2023 (filed on Dec 20, 2023)Insider Name:Doyle AnthonyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,482Price:$6.05
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4505 Emperor Blvd Ste 200 DURHAM NC 27703-8457 |
Tel: | 1-919-8597910 |
Website: | https://www.biocryst.com |
IR: | See website |
Key People | ||
Jon P. Stonehouse President, Chief Executive Officer, Director | Anthony J. Doyle Chief Financial Officer | Charles K. Gayer Chief Commercial Officer |
Helen M. Thackray Chief Research & Development Officer | Alane P. Barnes Chief Legal Officer, Corporate Secretary |
Business Overview |
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. |
Financial Overview |
For the fiscal year ended 31 December 2023, BioCryst Pharmaceuticals Inc revenues increased 22% to $331.4M. Net loss decreased 8% to $226.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development Expense decrease of 19% to $185.6M (expense), Interest and other income increase from $5.1M to $15.8M (income). |
Employees: | 536 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,308M as of Dec 31, 2023 |
Annual revenue (TTM): | $331.41M as of Dec 31, 2023 |
EBITDA (TTM): | -$102.05M as of Dec 31, 2023 |
Net annual income (TTM): | -$226.54M as of Dec 31, 2023 |
Free cash flow (TTM): | -$97.31M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $450.28M as of Dec 31, 2023 |
Shares outstanding: | 206,330,603 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |